常规超声对甲状腺滤泡病变的鉴别诊断价值研究

来源 :第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 | 被引量 : 0次 | 上传用户：tecra1234

【摘要】

：

　　目的：探讨常规超声对甲状腺滤泡病变鉴别诊断的价值。方法：选择2004年至2014年在北京协和医院就诊并被病理证实的59例滤泡癌，以性别、年龄作为匹配条件，随机从病历数据库中选

【作者】

：

吴琼姜玉新杨筱赖兴建朱沈玲张晓燕赵瑞娜张波

【机构】

：

北京中国医学科学院北京协和医院超声医学科

【出处】

：

第十八届全国临床肿瘤学大会暨2015年CSCO学术年会

【发表日期】

：

2015年9期

【关键词】

：

甲状腺滤泡病变超声鉴别诊断

下载到本地 , 更方便阅读

下载此文赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

　　目的：探讨常规超声对甲状腺滤泡病变鉴别诊断的价值。方法：选择2004年至2014年在北京协和医院就诊并被病理证实的59例滤泡癌，以性别、年龄作为匹配条件，随机从病历数据库中选择同时期的滤泡型乳头状癌、滤泡型腺瘤、结节性甲状腺肿伴腺瘤样增生各59例作为对照组，回顾性分析其超声声像图特征，寻找鉴别良恶性甲状腺滤泡病变的超声特征。

其他文献

Abundance of EGFR Mutations affects the efficacy of EGFR-TKI in patients with EGFR-Mutant advanced l

　　Objective: The discovery of epidermal growth factor receptor(EGFR) mutations in NSCLC opened the era of individualized therapy.A number of clinical studies

会议

Circulating Tumor Cells and Evaluation of Targeted Therapy Effect in EGFR Mutation/ALK Translocation

　　Objective: Targeted therapies have considerably improved the prognosis of patients with non-small cell lung cancer (NSCLC).Although not precision enough, RE

会议

中国非小细胞肺癌患者PD-L1的表达及与其它肺癌驱动基因的关系

　　目的：为了预估抑制PD-1/PD-L1单抗的单药治疗和/或联合治疗的受益人群,本研究对中国非小细胞肺癌患者进行了一系列肿瘤免疫治疗相关(PD-1,PD-L1和CTLA-4)和肿瘤靶向治疗相

会议

中国非小细胞肺癌患者PD-L1表达驱动基因治疗相关

Randomized trial of gefitinib with and without pemetrexed as first-line therapy in East-Asian patien

　　目的： Pemetrexed (P) is the standard of care for non-squamous non-small cell lung cancer (NS NSCLC)， whereas epidermal growth factor receptor (EGFR) tyrosine

会议

Moderate dose-fractionated stereotactic body radiotherapy for medically Inoperable stage Ⅰ non-small

　　Objective: To investigate the clinical outcomes and toxicity of stereotactic body radiotherapy (SBRT) with amoderate dose fraction for medically inoperable

会议

Phase Ⅲ trial of afatinib vs erlotinib in patients (pts) with squamous cell carcinoma (SCC) of the l

　　Objective: Treatment options for pts with advanced SCC of the lung progressing after platinum-based chemotherapy are limited.Over expression of EGFR, other

会议

Predicting Tissue c-Met Status Using Plasma Soluble c-Met Levels in Patients with advanced NSCLC

　　Objective: Immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) are reliable ways to identify over expression of c-Met protein or amplifi

会议

An ongoing phase 3b/4 safety trial of nivolumab (nivo) in patients (pts) with advanced or metastatic

　　Objective: Nivo, a fully human IgG4 programmed death-1 immune checkpoint inhibitor antibody, has demonstrated durable responses and tolerability in heavily

会议

Predictive and prognostic value of de novo MET expression in patients with advanced non-small cell l

　　Objective: The cellular-mesenchymal-epithelial transition protein (MET) has recently been identified as a novel promising target in non-small-cell lung canc

会议

Comprehensive genomic profiling of advanced cancers identifies MET exon 14 alterations that are sens

　　Objective: Amplifications and activating mutations in the c-MET proto-oncogene are known oncogenic drivers that have proven responsive to targeted therapy.

会议

常规超声对甲状腺滤泡病变的鉴别诊断价值研究

与本文相关的学术论文